Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates:

Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors

Disclosures

Introduction

SILEN-C1 trial

Virologic responsea

Methods

Baseline characteristics

Virologic response by age and gender

Virologic response by baseline ALT and GGT

Virologic response by baseline HCV RNA

Virologic response by HCV GT-1 subtype

Virologic response by IL28B

Baseline predictors of SVR

Baseline predictors of SVR

Discussion

Acknowledgements